# A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

> **NCT07218926** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 450 (estimated)

## Conditions studied

- Gastrointestinal Neoplasms

## Interventions

- **DRUG:** IDRX-42
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT07218926
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2028-05-30
- **Final completion:** 2030-11-29
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07218926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07218926, "A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07218926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*